Platform for Microbial-induced Allergen-specific Tolerance (MAT)

The project is aimed to develop a novel approach for allergen specific immunotherapy (ASIT), with several crucial advantages, compared to gold standard sublingual allergen immunotherapy: shorter treatment period with less frequent drug administration resulting in long-term complete remission. This could be achieved by redirection of the immune response to “non-allergic” mode via continuous exposure to the allergen together with bacterial stimuli in the local setting.